

AMENDMENTS TO THE SPECIFICATION

5 Please replace paragraph (00035) with the following amended paragraph:

(00035) Other embodiments include a method to enhance the expression of one or more cytokines or interleukins that facilitate Th1 immune responses in a subject or to reduce the expression of one or more cytokines or interleukins that
10 facilitate Th2 immune response in a subject comprising administering to the subject an effective amount of the composition of claim 32, whereby the subject's Th1 immune response is enhanced ~~or~~ or the subject's undesired Th2 immune response is reduced.

15 Please replace paragraph (000148) with the following amended paragraph:

(000148) Other embodiments include compounds compositions and formulations where one or more of R¹-R⁶, R¹⁰, R¹⁵, R¹⁷ and R¹⁸ comprise an
20 amino acid or a peptide, e.g., R¹, R² or R⁴ comprises an amino acid or a peptide, R³ is a halogen and R⁵ and R⁶ are both -CH₃. The peptide at one or more of R¹-R⁶ can comprise a cell surface binding peptide such as the entire protein or a sequence from fibronectin or retronectin, e.g., KQAGDV (SEQ ID NO 1).

25 Please replace paragraph (000202) with the following amended paragraph:

(000202) **Groups 37-1 through 37-25-10-6.** These groups comprise each compound named in all of the ~~compound~~-compound groups 1 through 36-25-10-
30 6 described above wherein R¹ is not divalent, e.g., is not =O, and it is in the α -configuration, instead of the β -configuration as shown in formula B.